Stockscreener 앱 받기
2.50
1.21%
0.03
시간 외 거래:
2.50
전일 마감가:
$2.47
열려 있는:
$2.48
하루 거래량:
105.49K
Relative Volume:
0.41
시가총액:
$24.40M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-3.3333
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
+6.84%
1개월 성능:
+41.24%
6개월 성능:
+19.05%
1년 성능:
-75.85%
1일 변동 폭
$2.39
$2.60
1주일 범위
$2.25
$2.60
52주 변동 폭
$1.17
$12.53
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.50 | 24.11M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Instil Bio Terminates License and Collaboration Agreement With ImmuneOnco Biopharmaceuticals - TradingView — Track All Markets
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
How a $2 million payment wiped out $10.6 million in company debt - Stock Titan
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development - Quantisnow
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade - ts2.tech
The economy: Top biopharma trends of 2025 - BioWorld MedTech
Layoff Tracker: Nido Will Close Following Lead Candidate’s Disappointing Phase II Results - BioSpace
Intelligent Bio Solutions Inc Announces New Manufacturing Partnership - TradingView — Track All Markets
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
ImmunityBio (NASDAQ: IBRX) boosts ATM capacity and ups authorized shares - Stock Titan
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - Улправда
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Why GRI Bio Inc. stock remains on buy listsShare Buyback & Stepwise Trade Signal Implementation - Улправда
How sustainable is TELA Bio Inc. stock dividend payout2025 Pullback Review & Low Risk High Win Rate Picks - Улправда
Korro Bio (KRRO) boosts Jeffrey Cerio salary, severance and RSU grant - Stock Titan
Can Third Harmonic Bio Inc. stock withstand economic slowdownTrade Risk Assessment & Reliable Entry Point Alerts - Улправда
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
BioCardia (NASDAQ: BCDA) moves to PMDA consultation on heart failure therapy - Stock Titan
Owner RA Capital Management LP Buys 314,561 ($754.7K) Of Climb Bio Inc [CLYM] - TradingView — Track All Markets
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
BioXcel Therapeutics (NASDAQ: BTAI) wins approval for reverse stock split plan - Stock Titan
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com India
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
GRI Bio (Nasdaq: GRI) reports positive IPF Phase 2a results and warrant offering - Stock Titan
The 4 billion won investment quietly implemented by Yuhan four years ago returned to a "large jackpo.. - 매일경제
Pres Kalowski Sells 9,072 ($31.4K) Of Q32 Bio Inc [QTTB] - TradingView
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO (NASDAQ: KALA) prices $10M registered direct sale of 10M shares at $1.00 - Stock Titan
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):